Pharmaceuticals
Jazz Pharmaceuticals PLC (JAZZ)
HOLD. 12-month probability-weighted target $245 (+12% vs spot). P/E Multiple explains 90% of Monte Carlo outcome variance.
Zoetis Inc (ZTS)
HOLD. 12-month probability-weighted target $74 (-1% vs spot). P/E Multiple explains 76% of Monte Carlo outcome variance.
Viatris Inc (VTRS)
HOLD. 12-month probability-weighted target $20 (+11% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.
Bristol-Myers Squibb Company (BMY)
HOLD. 12-month probability-weighted target $56 (-6% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.
Elanco Animal Health (ELAN)
HOLD. 12-month probability-weighted target $25 (+7% vs spot). Gross Margin explains 51% of Monte Carlo outcome variance.
Johnson & Johnson (JNJ)
HOLD. 12-month probability-weighted target $236 (-10% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.
Eli Lilly and Company (LLY)
HOLD. 12-month probability-weighted target $1084 (-8% vs spot). P/E Multiple explains 86% of Monte Carlo outcome variance.
Pfizer Inc (PFE)
SELL. 12-month probability-weighted target $23 (-19% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.
Merck & Company Inc (MRK)
SELL. 12-month probability-weighted target $120 (-17% vs spot). P/E Multiple explains 65% of Monte Carlo outcome variance.